The effects of 6-gingerol on proliferation, differentiation, and maturation of osteoblast-like MG-63 cells.
We investigated whether 6-gingerol affects the maturation and proliferation of osteoblast-like MG63 cells in vitro. Osteoblast-like MG63 cells were treated with 6-gingerol under control conditions, and experimental inflammation was induced by tumor necrosis factor-α (TNF-α). Expression of different osteogenic markers and cytokines was analyzed by real-time PCR, Western blotting, and enzyme-linked immunosorbent assay. In addition, alkaline phosphatase (ALP) enzyme activity and biomineralization as markers for differentiation were measured. Treatment with 6-gingerol resulted in insignificant effects on the proliferation rate. 6-Gingerol induced the differentiation of osteoblast-like cells with increased transcription levels of osteogenic markers, upregulated ALP enzyme activity, and enhanced mineralized nodule formation. Stimulation with TNF-α led to enhanced interleukin-6 and nuclear factor-κB expression and downregulated markers of osteoblastic differentiation. 6-Gingerol reduced the degree of inflammation in TNF-α-treated MG-63 cells. In conclusion, 6-gingerol stimulated osteoblast differentiation in normal physiological and inflammatory settings, and therefore, 6-gingerol represents a promising agent for treating osteoporosis or bone inflammation.
Department of Orthopedic Surgery, First Affiliated Hospital, Harbin Medicine University, Harbin, China.
J Z
JZ
Fan
Department of Orthopedic Surgery, First Affiliated Hospital, Harbin Medicine University, Harbin, China.
X
X
Yang
Department of Orthopedic Surgery, First Affiliated Hospital, Harbin Medicine University, Harbin, China.
Z G
ZG
Bi
D000469:Alkaline Phosphatase / Q000032:analysis; D015153:Blotting, Western; D002396:Catechols / Q000494:pharmacology* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005233:Fatty Alcohols / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy; D060888:Real-Time Polymerase Chain Reaction; D015203:Reproducibility of Results; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects
D002396:Catechols; D024042:Collagen Type I; D005233:Fatty Alcohols; D014409:Tumor Necrosis Factor-alpha; C007845:gingerol; D000469:Alkaline Phosphatase